



Tatva Chintan Pharma Chem Limited
(Formerly known as Tatva Chintan Pharma Chem Private Limited)
(CIN:L24232GJ1996PLC029894)



BY ELECTRONIC MODE

January 17, 2022

Ref No: TCPCL/SEC/2021-22/00060

To,

<p>The General Manager, Corporate relationship department, BSE Limited</p> <p>Phiroze Jeejeebhoy Towers, Dalal Street, Fort, Mumbai-400 001</p> <p>Scrip Code: 543321 Through: BSE Corporate Compliance & Listing Centre</p>	<p>The Manager, Listing department, National Stock Exchange of India Limited</p> <p>Exchange Plaza, C-1, Block-G, Bandra-Kurla, Complex Bandra(E), Mumbai-400 051</p> <p>Scrip Symbol: TATVA Through: NEAPS</p>
--	--

Subject: Press Release on the financial results


Dear Sir/Madam,

Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, please find enclosed a copy of the Press Release on the financial results of the Company for the quarter and nine months ended December 31, 2021.

The same will also be available on the Company's website, "www.tatvachintan.com".

This is for your information and records.

Thanking You,
For Tatva Chintan Pharma Chem Limited


Ishwar Nayi
Company Secretary
M No.: A37444



Factory and Registered Office : Plot No. 502/17, G.I.D.C. Estate, Ankleshwar - 393 002, District : Bharuch, Gujarat, India.
SEZ Unit : Plot No. Z/103/F/1 and Plot No. Z/103/F/2, SEZ Area, Part-2, Dahej - 392 130, District : Bharuch, Gujarat, India.
DSIR Approved R & D Center : Plot No. 353, G.I.D.C., Makarpura, Vadodara - 390 010, Gujarat, India.

Telephone No. : +91 75748 48533 / 34 **Fax :** +91 265 263 8533
E-mail : chintan@tatvachintan.com **Website :** www.tatvachintan.com



Tatva Chintan Pharma Chem Limited Reports Q3FY22 Financial Results

Revenue grew 31% to ₹1,047 Mn on Y-o-Y basis
Profit After Tax at ₹228 Mn; growth of 9% Y-o-Y

Vadodara, 17th January 2022: Tatva Chintan Pharma Chem Limited (TCPCL) BSE: 543321, NSE: TATVA, ISIN: INEOGK401011, an integrated speciality chemical company, has announced its financial results for the third quarter and nine months ended on 31st December 2021, as approved by the Board of Directors.

Consolidated Results at Glance (Y-O-Y – Q3FY22 COMPARED WITH Q3FY21)

- Revenue from Operations for the quarter was ₹ 1,046.70 million higher by 31%
- EBITDA for the quarter was ₹ 285.32 million higher by 13%
- EBIDTA Margin for the quarter was at 27.26%
- Net Profit for the quarter was ₹ 228.07 million higher by 9%
- Net Profit Margin for the quarter was at 21.79%
- Basic and Diluted EPS for the quarter was ₹ 10.29 per share

Consolidated Results at Glance (Y-O-Y – 9MFY22 COMPARED WITH 9MFY21)

- Revenue from Operations for the nine months was ₹ 3,351.17 million higher by 75%
- EBITDA for the nine months was ₹ 948.27 million higher by 113%
- EBIDTA Margin for the nine months was at 28.30%
- Net Profit for the nine months was ₹ 783.64 million higher by 152%
- Net Profit Margin for the nine months was at 23.38%
- Basic and Diluted EPS for the nine months was ₹ 36.82 per share

Commenting on the Q3 & 9M performance Mr. Chintan Shah, Managing Director, said, during the quarter I am pleased to inform you that we are very well on our way of being recognized as a niche player in the speciality chemical space with our focus on manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts, Pharma & Agrochemical Intermediates and Speciality Chemicals with PTC comprising 24%, SDAs comprising 51%, Electrolyte Salts comprising 2% and PASC comprising 22% of the revenue taking the revenue till date i.e. 9MFY22 at ₹ 3,351.17 million as compared to 3,003.59 million during FY21. The company posted an EBIDTA margin of 28.30% during 9MFY22 as compared to 23.85% during FY21. During the quarter, exports comprised 80% of the revenue.

We have a clear focus on adopting green chemistry processes supported by our state-of-the-art research and development facility and manufacturing plants. With the wide range of applications of our products, TCPCL can cater to customers across wide spectrum of chemical Industries which ensures a sustainable business model. Diversified product portfolio has helped accelerate our growth. We got listed on NSE/BSE on 29 July 2021, out of our net IPO proceeds of ₹ 2,072.81 million, ₹ 114.53 million have been utilized during Q3FY22 taking the total amount utilized to ₹ 511.38 million as on 31 December 2021. The capacity expansion is underway at our Dahej SEZ manufacturing plant and at our R&D facility at Vadodara.

During the quarter, we appointed Mr Ashok Bothra as Chief Financial Officer (CFO) and Key Managerial Personnel (KMP) of the company with effect from 3rd December 2021.



About Tatva Chintan Pharma Chem Limited (TCPCL):

TCPCL is an Integrated Specialty Chemical company, present across the value chain manufacturing Phase Transfer Catalyst, Structure Directing Agents, Electrolyte Salts and Pharma & Agrochemical Intermediates and Specialty Chemicals, established in the year 1996 by first generation entrepreneur engineers. It has two manufacturing facilities at Ankleshwar and Dahej SEZ, Gujarat with an existing combined installed reactor capacity of 280KL and 29 Assembly Lines, having Sophisticated R&D Unit recognized by DSIR at Vadodara, Gujarat. TCPCL has a customer base spanning over 25 Countries including USA, UK, China, Germany, Japan and South Africa. Exports constitute 71% of the total revenue during FY21. The Company is focused on serving customers across broad spectrum of chemical industries with applications in automotive, petrochemicals, pharmaceutical, agrochemicals, paints and coatings, dyes and pigments, personal care, and flavors & fragrances. For more information, please visit: www.tatvachintan.com

For Further details, please get in touch with:



Dinesh Sodani
Tatva Chintan Pharma Chem Limited
Email: finance1@tatvachintan.com



Krishna Patel / Rahul Thakkar
Christensen Advisory
kpatel@christensenir.com/
rthakur@christensenir.com

Cautionary Statement:

This press release contains certain forward-looking statements. Any forward-looking statement applies only on the date of this press release. By their nature, forward looking statements are subject to several known and unknown risks and uncertainties that may or may not occur in the future and as a result of which the actual results and performance may differ substantially from the expected future results or performance expressed or implied in the forward - looking statements. No warranties or representations are made as to the accuracy, achievement, or reasonableness of such statements, estimates or projections, and Tatva Chintan Pharma Chem Limited has no obligation to update any such information or to correct any inaccuracies herein or omission here from which may become apparent.